The physiological and pharmacological roles of cytochrome P450 isoenzymes

Anaesthesia

Volumn 54, Issue 1, 1999, Pages 42-50

  Chang, G W M ^a   Kam, P C A ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Enzymes, cytochrome P450

Indexed keywords

ARACHIDONIC ACID; BILE ACID; CYTOCHROME P450 ISOENZYME; HEMOPROTEIN; ISOENZYME; STEROID HORMONE;

ARTICLE; BILE ACID SYNTHESIS; CENTRAL NERVOUS SYSTEM FUNCTION; ENZYME ACTIVITY; HORMONE SYNTHESIS; METABOLISM; PROTEIN FAMILY;

ANESTHETICS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES;

EID: 0032937986     PISSN: 00032409     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2044.1999.00602.x     Document Type: Article

References (50)

1. Gonzalez FJ. The molecular biology of cytochromes P450s. Pharmacological Reviews 1989; 40: 243-88.
2. Kerremans ALM. Cytochrome P450 isoenzymes -importance for the internist, Netherlands Journal of Medicine 1996; 48: 237-43.
3. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Annals of Pharmacotherapy 1995; 29: 619-24.
4. Guengerich FP. Characterization of human cytochrome P450 enzymes. FASEB Journal (Bethesda, MD) 1992; 6: 745-8.
5. Waterman MH. Introduction: transcription and regulation of activities of cytochromes P450, metabolizing endogenous substrates. FASEB Journal (Bethesda, MD) 1996; 10: 1455.
6. Makita K, Falck JR, Capdevila JH. Cytochrome P450, the arachidonic acid cascade, and hypertension: new vistas for an old enzyme system. FASEB Journal (Bethesda, MD) 1996; 10: 1456-63.
7. Simpson ER, Michael MD, Agarwal VR, Hinshelwood MM, Bulin SE, Zhao Y. Expression of the CYP19 (aromatase) gene: an unusual case of alternative promoter usage. FASEB Journal (Bethesda, MD) 1997; 11: 29-36.
8. Nelson DR, Koymans L, Kamtaki T, et al. P 450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Phamacogenetics 1996; 6: 1-42.
9. Ortiz de Montellano PR. The 1994 Bernard B Brodie Award Lecture. Structure, Mechanism, and Inhibition of Cytochrome P450. Drug Metabolism and Disposition 1995; 23: 1181-7.
10. Guengerich FP, MacDonald TL. Mechanisms of cytochrome P450 catalysis. FASEB Journal (Bethesda, MD) 1990; 4: 2453-9.
11. Gonzalez FJ. Human cytochromes P450; problems and prospects. Trends in Pharmacological Sciences 1992; 13: 346-52.
12. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Critical Reviews in Texicology 1992; 22: 1-21.
13. Murray M. P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease. Clinical Pharmacokinetics 1992; 23: 132-46.
14. Yang CS, Brady JF, Hong JY. Dietary effects on cytochromes P450, xenobiotic metabolism and toxicity. FASEB Journal (Bethesda, MD) 1992; 6: 737-44.
15. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clinical Pharmacokinetics 1994; 26: 144-60.
16. Warner M, Stromstedt M, Wyss A. Gustafsson J-A. Regulation of cytochrome P450 in the central nervous system. Journal of Steroid Biochemistry and Molecular Biology 1993; 47: 191-4.
17. Kroemer HK, Eichelbaum M. "It's the genes, stupid." Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sciences 1995; 566: 2285-98.
18. Nemeroff CB, DeVane L, Pollock BG. Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry 1996; 153: 311-20.
19. Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiological Reviews 1997; 77: 517-44.
20. Rowland M, Tozer TN. Genetics. In Clinical Pharmacokinetics. Concepts and Applications. Baltimore: Williams and Wilkins, 220-9.
21. Coon MJ, Ding X, Pernecky SJ, Vaz ADN. Cytochrome P450; progress and predictions. FASEB Journal (Bethesda, MD) 1992; 6: 669-73.
22. Morhashi K-I, Omura T. Ad4BP/SF-1, a transcriptional factor essential for the transcription of steroidogenic cytochrome P450 genes and for the establishment of the reproductive function. FASEB Journal (Bethesda, MD) 1996; 10: 1569-77.
23. Waterman MR, Bischof LJ. Diversity of ACTH(cAMP)-dependent transcription of bovine hydroxlase genes. FASEB Journal (Bethesda, MD) 1997; 11: 419-27.
24. Capdevila JH, Falck JR, Estabrook RW. Cytochrome P450 and the arachidonate cascade. FASEB Journal (Bethesda, MD) 1992; 6: 731-6.
25. Javitt NB. Bile acid synthesis from cholesterol: regulatory and auxillary pathways. FASEB Journal (Bethesda, MD) 1994; 8: 1308-11.
26. Stadler J, Trockfeld J, Schmalix WA, et al. Inhibition of cytochromes P4501A by nitric oxide. Proceedings of the National Academy of Sciences USA 1994; 91: 3559-63.
27. Koop DR. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB Journal (Bethesda, MD) 1992; 6: 724-30.
28. Kharasch ED, Karol MD, Lanni C, Sawchuk R. Clinical sevoflurane metabolism and disposition II. The role of cytochrome P450 2E1 in fluoride and hexafluoroisopropanol formation. Anesthesiology 1995; 82: 1379-88.
29. Kharasch ED, Thummel KE. Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance? Anesthesia and Analgesia 1993; 76: 1033-9.
30. Oda Y, Furuichi K, Tanaka K, et al. Metabolism of a new local anaesthetic, ropivacaine, by human hepatic cytochrome P450. Anesthesiology 1995; 82: 214-20.
31. Soutaniemi EA, Rautio A. Backstrom M, Arvela P, Pelkonen O. CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. British Journal of Pharmacology 1995; 39: 71-6.
32. Paine MF, Shen DD, Kunze KL, et al. First pass metabolism of midazolam by the human intestine. Clinical Pharmacology and Therapeutics 1996; 60: 14-24.
33. Jones DR. Gorski JC, Haehner BD, O'Mara EM, Hall SD. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation. Clinical Pharmacology and Therapeutics 1996; 60: 374-84.
34. Hase I, Oda Y, Tanaka K, Mizutani K, Nakamoto T, Asada A. I.V. fentanyl decreases the clearance of midazolam. British Journal of Anaesthesia 1997; 79: 740-3.
35. Janicki PK, James MFM, Eskine WAR. Propofol inhibits enzymatic degradation of alfentanil and sufentanil by isolated liver microsomes in vitro. British Journal of Anaesthesia 1992; 69: 311-2.
36. Chen TL, Ueng TH, Chen SH, Lee PH, Fan SZ, Liu CC. Human cytochrome P450 mono-oxygenase system is suppressed by propofol. British Journal of Anaesthesia 1995; 74: 558-62.
37. Kharasch ED, Karol MD, Lanni C, Sawchuk R. Clinical sevoflurane metabolism and disposition I. Anesthesiology 1995; 82: 1369-78.
38. Kharasch ED, Hankins DC, Thummel KE. Human kidney methoxyflurane and sevoflurane metabolism: intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology 1995; 82: 607-8.
39. Eliasson E, Kenna JG. Cytochrome P450 2E1 is a cell surface autogen in halothane hepatitis. Molecular Pharmacology 1996; 50: 573-82.
40. Wadelius M, Darj E, Frenne G, Rane A. Induction of CYP2D6 in pregnancy. Clinical Pharmacology and Therapeutics 1997; 62: 400-40.
41. Stromsdedt M, Warner M, Banner CD, Macdonald PC, Gustafsson JA. Role of brain cytochrome P450 in the regulation of the level of anaesthetic steroids in the brain. Molecular Pharmacology 1993; 44: 1077-83.
42. Poulsen L, Arendt-Nielson L, Brosen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clinical Pharmacology and Therapeutics 1996; 60: 636-14.
43. Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. Journal of Pharmacology and Experimental Therapeutics 1996; 278: 1165-74.
44. Otton SV, Schadel M, Cheung SW, Kaplan HL, Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clinical Pharmacology and Therapeutics 1993; 54: 463-72.
45. Wu D, Otton SV, Sproule BA, Busto U, Inaba T, Kalow W, Sellers EM. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. British Journal of Clinical Pharmacology 1993; 35: 30-4.
46. Kellerman G, Shaw CR, Luyten-Kellermann M. Aryl hydrocarbon hydroxylase inducibility and bronchogemc carcinoma. New England Journal of Medicine 1973; 298: 934-7.
47. Ayesh R, Idle JR, Ritchie JC. Metabolic oxidation phenotypes and markers for the susceptibility to lung cancer. Nature 1984; 312: 169-70.
48. McKay JA, Melvin WT, Ah-See AK, et al. Expression of cytochrome P450 CYP1B1 in breast cancer. FEBS Letters 1995; 374: 270-2.
49. Smith CAD, Gough AC, Leigh PN, Summers BA, Harding AE, Maranganore DM. Debrisoquine hydroxylase gene polymorphisms and susceptibility to Parkinson's disease. Lancet 1992; 339: 1375-7.
50. White PC, New MI, Dupont B. Congenital adrenal hyperplasia. New England Journal of Medicine 1987; 316: 1519-24.